180 Life Sciences Corp (ATNF) Price

180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company is headquartered in Palo Alto, California. The company went IPO on 2017-06-07. The firm is focused on iGaming sector, through its iGaming Technology Platform. The firm also continues to evaluate monetization strategies for its biotechnology assets.